There's a saying that investors should never try to catch a falling safe. To elaborate on that phrase, we like to let the safe hit the ground, see a few dollars fall out, and then walk up and collect a portion of the loot. Show More
Profit reporting season looked great from a distance but down in the trenches investors may not have felt that was quite the case. The data shows, on a stock-by-stock or even-weighted basis, that there has been a tempering of expectations across most sectors. Show More
The healthcare sector recorded a total gain of 24.4% in 2017, making it the single best performing sector on the ASX. Not even two months into 2018, and it is already a solid 10% ahead of the wider market. Yesterday's half-billion dollar takeover for Viralytics - at a 175% premium... Show More
The healthcare sector has been very strong this year, and here we touch on eight players within it. There have also been a couple of laggards in that space too, and they are the IVF players. So we've been sitting with neutral recommendations on the space the last two years.... Show More
Removing a company's debt burden can mark a turnaround for the share price, and in this wire, we discuss this and highlight three examples including one currently in play. Show More
Radiology and diagnostic imaging service provider, Capitol Health (CAJ), has announced their preliminary full year EBITDA result of $22m, 10% ahead of prior guidance. Along with the previously announced sale of their NSW assets (settling August 2017), the company’s total debt of $50m will be eliminated taking the business to... Show More
With reporting season in full swing the flow of company results is picking up and keeping the investment team busy. In this week’s report we provide a brief summary on the key takeaways from Capitol Health and NAB. Show More
As reporting season picks up pace, each week Livewire will ask a different panel of Managers for THE standout result of the week. Read on for two small-cap healthcare stocks, and a global funds business. Responses from Dean Fergie, Cyan Investment; John Murray, Perennial Value; and Simon Shields, Monash Investors. Show More
On Thursday, Capitol Health Limited (ASX: CAJ) announced the sale of its NSW assets to I-Med Radiology Network for $81.5 million which is more than 8.5 times expected FY17 earnings before interest, tax, depreciation and amortisation (EBITDA). We believe Capitol Health’s strong balance sheet and high cash levels will provide... Show More
After a brutal ‘confession season’, the small cap market is littered with former market darlings now trading more than 30% off their recent highs. So in this episode of Buy Hold Sell, two small cap specialists, Simon Shields from Monash Investors and Dean Fergie from Cyan Investment Management, talk us... Show More
Register or Login to access this premium content
Livewire brings together the insights of more than 100 leading investment professionals to one platform and a daily newsletter.
Registration is FREE.
Already a member? Sign in.
A fiery AGM day today - and at Jervois Mining shareholders didn't wait until next week's AGM to spill the Board. First strikes at Capitol Health, Carpentaria Exploration and RedHill Education. Second strike and Board Spill resolution passed at Ambertech; a second strike but no Board Spill at Cape Lambert... Show More
The healthcare sector has been one of the most consistent performers over the past 10 years, underperforming the ASX200 only 2 times over the past decade. However, increased regulatory scrutiny and soft industry data have taken some gloss off the domestic service providers (SHL, PRY, RHC, HSO, CAJ, IDX), with... Show More
The latest corporate reporting season has just ended. As usual the announced results are a case of the good, the bad and the ugly. The good are the star stocks that have delivered solid earnings results and increased their dividend payouts to their investors; the bad are those that have... Show More
Capitol Health has updated the market on its FY15 unaudited results. Key points revenue of $111.2m (up 23% on FY14 and higher than our forecast of A$108.8m) - driven by above system organic growth (8%) and from acquisitions. Underlying NPBT before acquisitions is A$16.1m (up 58% on pcp and higher... Show More